



Zorecimeran – Product information

-Strictly confidential-



Forward Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the "company") contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potency efficacy of the company's vaccine candidate and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements.


Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.



Company Overview and Status

CureVac at a Glance



Execution Power Provided by Bayer's Large-Pharma Infrastructure



Collaboration and Services Agreement

Announced January 7, 2021

- **Expertise and Infrastructure**

Adding **operational knowledge**, broad **international reach** and regional access to support global supply of CureVac's CVnCoV

- **Product Development Support**

Adding muscle in areas such as **clinical operations, regulatory affairs, pharmacovigilance, and supply chain performance**

- **Key Territory Operations**

Adding country support for **EU member states and beyond**

CureVac to be Market Authorization Holder, option for Bayer in other markets outside the EU



Scaling-up a Broad and High-Performing Manufacturing Network




- Network of highly experienced CDMO partners for key manufacturing steps
- Flexible network expected to serve a variable demand, while mitigating supply chain risks
- Expected network annual output of up to 300m doses in 2021 and up to 1 billion doses in 2022












RNA Printer™
Fully automated, mobile
GMP-grade manufacturing

- Pandemic preparedness
- Customized therapeutics
- Clinical development



CVnCoV - Progress and Path Towards Approval



-  **Jan 2020** **Design** of multiple vaccine candidates
-  **Mar 2020** **Lead candidate** selection out of several candidates
-  **Jun 2020** **First GMP production** of lead candidate
-  **Jun 2020** **Start of Phase 1** dose escalation clinical trial
-  **Sep 2020** **Start of Phase 2a** clinical trial in older adults
-  **Nov 2020** **Interim Phase 1 data** and final dose selection
-  **Nov 2020** **European network** for CVnCoV manufacturing
-  **Dec 2020** **Start of pivotal Phase 2b/3** safety and efficacy clinical trial
-  **Feb 2021** **Initiation of Rolling Submission** with EMA

HERALD-004: Clinical Development of COVID-19 Vaccine Candidate, CVnCoV



Pivotal Phase 2b/3 Clinical Trial HERALD - Ongoing since December 2020

Expected number of participants:

More than 35,000

Global trial to be conducted in

Europe, Latin America

Event-driven interim analysis

Potentially end of Q1 2021

Phase 2b part of the trial

- Randomized 1:1 to receive 2 doses of CVnCoV or control
- Subjects stratified according to age: ≥ 18 and ≥ 60 years
- Testing for safety, reactogenicity and immunogenicity

Phase 3 part of the trial

- Randomized 1:1 to receive 2 doses of CVnCoV or control
- Subjects stratified according to age: ≥ 18 years
- Testing for safety and efficacy

A scientist in a white lab coat and safety glasses is working in a laboratory. He is wearing green gloves and is holding a pipette. He is looking at a piece of laboratory equipment, possibly a pipette or a small incubator. The background is a blurred laboratory setting with various pieces of equipment and shelves.

Product Information

10 - 12

5.1.1c



Supply Details

UREVAC
Live TASA people?

14 - 14

5.1.1c



**Thank you for your
attention**

CureVac
www.curevac.com